NASM: GLP-1 Medications Transform Fitness Professionals' Roles
The National Academy of Sports Medicine (NASM) has identified GLP-1 medications, also known as GLP1 receptor agonists, as a significant challenge and opportunity for personal trainers. As these drugs gain prominence, fitness professionals are adapting their roles to meet evolving client needs.
GLP1 receptor agonists, initially developed for diabetes management, are now being explored for weight loss. However, their rise presents challenges and opportunities for fitness professionals. NASM's recent survey found that 74% of fitness professionals agree collaboration with medical providers is now essential.
NASM has responded to this shift by creating a specialized course, 'Understanding Weight Loss Medications', to help trainers navigate the complexities of GLP1 receptor agonists. Meanwhile, the fitness equipment market is projected to grow by over $8 billion by 2030, reflecting industry expansion.
Several pharmaceutical companies, including Eli Lilly with its late-stage candidate Orforglipron, are developing GLP1 receptor agonists. BioNxt Solutions plans pilot studies for an oral Semaglutide film next year. However, not all developments are successful; Pfizer's Danuglipron was stopped in 2025 due to side effects. New therapies like the oral Semaglutide film and Orforglipron could become available within the next few years.
Despite their potential, Americans remain skeptical of GLP1 receptor agonists, with nearly three-quarters viewing them as a shortcut and 60% concerned they may bypass healthy habits. Fitness professionals are evolving their roles, with 46% seeing longevity and strength training as the industry's biggest opportunity. The rise of GLP1 receptor agonists is now the second-largest challenge, behind artificial intelligence. Nearly 70% of fitness professionals expect their role to shift away from calorie burning and weight loss towards strength training and longevity coaching. Preserving lean mass is clients' biggest concern due to GLP1 use, reported by 60% of fitness professionals.
As GLP1 receptor agonists become more prevalent, fitness professionals are adapting their roles to support clients effectively. Specialized training, like NASM's course, and collaboration with medical providers are crucial in this evolving landscape. The fitness industry's growth and the shift in professionals' roles reflect the impact of these medications on health and fitness.
Read also:
- Qur'an Emphasizes Fatherhood Through Stories of Prophets
- Capella Nursing Students Gear Up for Crucial FPX 4050 Assessments
- Comprehensive Overview of Addressing Traumatic Brain Injuries (TBIs)
- Enhanced Health Services Provisioned by San Diego Academic Health Partnership Continues During COVID-19 and Beyond
